[{"id":"cc241a5c-7c68-406b-b95d-f9f314fccafd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03939182","created_at":"2021-02-03T10:56:06.215Z","updated_at":"2024-07-02T16:34:36.776Z","phase":"Phase 1","brief_title":"Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma","source_id_and_acronym":"NCT03939182","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BCL6 • IRF4 • MME","pipe":"","alterations":" ","tags":["BCL6 • IRF4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • abexinostat (CG-781)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 05/29/2019","start_date":" 05/29/2019","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-06-10"},{"id":"b3f6e3f3-f8b2-4cd5-bf36-ab5083891e9e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03590054","created_at":"2021-01-18T17:39:18.307Z","updated_at":"2024-07-02T16:35:13.120Z","phase":"Phase 1","brief_title":"Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies","source_id_and_acronym":"NCT03590054","lead_sponsor":"Rahul Aggarwal","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • abexinostat (CG-781)"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 08/20/2018","start_date":" 08/20/2018","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 11/30/2023","study_completion_date":" 11/30/2023","last_update_posted":"2024-03-22"},{"id":"a1f920d4-f11b-445c-a399-3c6531c82e73","acronym":"","url":"https://clinicaltrials.gov/study/NCT04498520","created_at":"2021-01-18T21:33:07.867Z","updated_at":"2024-07-02T16:36:30.083Z","phase":"Phase 1","brief_title":"Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer","source_id_and_acronym":"NCT04498520","lead_sponsor":"Pamela Munster","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 amplification • HER-2 negative • PGR expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 amplification • HER-2 negative • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • abexinostat (CG-781)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/31/2021","start_date":" 03/31/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2021-05-18"}]